Detailed Quote:IPIX INNOVATION PHARMACEUTICALS

New Post Public Reply Private Reply Replies (1) Message Board

Nov 2, 2018 at 7:27 PM 511

Detailed Quote:IPIX
INNOVATION PHARMACEUTICALS INC
0.187Up 0.057 (43.85 %)AS OF 3:59:45PM ET 11/02/2018

Last Trade 0.187
Trade Time 3:59:45pm ET

Change 0.057
% Change 43.85%

Bid 0.1755
Bid Size 5000

Ask 0.187
Ask Size 5000

Open 0.13
Day High 0.189 ** .061c *liquidity*
Day Low 0.128
Previous Close
11/01/2018 0.13
52-Week High
12/06/2017 1.17
52-Week Low
10/19/2018 0.12

Price Performance (Last 52 Weeks)
11/01/2018 -82.55%

Volume 1,372,537
Volume (10 day Average) 841,159
Volume (90 day Average) 421,961

last grab B/A .. may not align with Fido's above

 
 
NITE	0.1755	5,000	15:58 
 
CSTI	0.175	5,000	15:56 
 
ETRF	0.175	5,000	15:59 
 
CDEL	0.15	37,230	15:59 
 
VERT	0.125	5,000	10:14 
 
LAFC	0.1103	5,000	10/19 
 
VNDM	0.102	5,000	11/01 
 
STXG	0.1012	5,000	09/28 
 
PUMA	0.10	5,000	08:10 
 
MAXM	0.0001	10,000	07:35 
 
CANT	0.0001	10,000	15:46 
 
DBOX	U	0	10/15 
 
INTL	U	0	10/24 
 
OTCX	U	0	08:15 
 
 
 
CDEL	0.187	9,000	15:59 
 
NITE	0.187	5,000	15:57 
 
CSTI	0.188	10,000	15:57 
 
ETRF	0.189	10,000	15:56 
 
VNDM	0.23	2,500	11/01 
 
LAFC	0.35	2,500	10/02 
 
PUMA	0.35	2,500	08:10 
 
CANT	0.36	5,000	11:07 
 
VERT	0.36	2,500	10:13 
 
STXG	2.00	100	>year 
 
MAXM	8.00	100	07:35 
 
DBOX	U	0	10/15 
 
INTL	U	0	10/24 
 
OTCX	U	0	08:15

email in @ 7:30AM

Innovation Pharmaceuticals Submits End of Phase 2 "Briefing Package" to FDA.
Fri, Nov 2, 2018 7:30 am

Dear Innovation Pharmaceuticals Shareholders,

Earlier this week, the company submitted the “briefing package” for our scheduled End-of-Phase 2 meeting to be held later this quarter with the FDA. This is an exciting milestone in the development of oral rinse Brilacidin for the treatment of Oral Mucositis.

A successful FDA meeting would be transformative for our company, opening up enormous potential for our shareholders and, more importantly, for patients who need such a treatment.

I wish to remind shareholders of the results achieved in the Phase 2 study with Brilacidin. In Head and Neck Cancer patients receiving cisplatin administered in a higher concentration (80-100 mg/m2), approximately every 21 days, oral rinse Brilacidin’s results were as follows:

In the Modified Intention-to-Treat population, 71.4% of patients receiving placebo developed severe Oral Mucositis, compared to 25.0% of patients receiving Brilacidin [mITT Population] (p=0.048).
In the Per Protocol population, 72.7% of patients receiving placebo developed severe Oral Mucositis, compared to 14.3% of patients receiving Brilacidin [PP Population] (p=0.025).

The stark difference between how our drug performed against placebo will be a focus of our FDA meeting and provides us with a high-degree of confidence in the treatment potential and commercial value of our asset. As we have shared previously, our research shows there is a significant market opportunity for treating Oral Mucositis in Head and Neck Cancer patients receiving chemoradiation, as there currently is no FDA-approved drug. Of course, there are no assurances stated or implied regarding successfully developing a drug, but if we are successful, we believe that earnings from a new, easy-to-use OM drug could be many multiples of our present market cap. This keeps us driving forward in executing on our business model and building shareholder value.

In our next corporate filing (10q), we will be updating shareholders on other ongoing business and clinical development priorities.

11.2.18 .. trades .. markage @ 29.30%

 
 
15:59:45		0.187	1000	OTO 
 
15:59:25		0.187	11580	OTO 
 
15:59:20		0.18125	3420	OTO 
 
15:59:14		0.176	5000	OTO 
 
15:59:14		0.18	16580	OTO 
 
15:59:03		0.187	5000	OTO 
 
15:59:00		0.187	2500	OTO 
 
15:59:00		0.187	3000	OTO 
 
15:58:11		0.18	600	OTO 
 
15:58:09		0.181	400	OTO 
 
15:58:09		0.181	5000	OTO 
 
15:57:49		0.18	5500	OTO 
 
15:57:14		0.187	1000	OTO 
 
15:57:09		0.18	10000	OTO 
 
15:56:12		0.187	5000	OTO 
 
15:56:11		0.189	10000	OTO 
 
15:56:03		0.187	10000	OTO 
 
15:53:37		0.187	21500	OTO 
 
15:53:34		0.186	28500	OTO 
 
15:53:02		0.186	500	OTO 
 
15:52:49		0.18	5000	OTO 
 
15:51:49		0.185	1000	OTO 
 
15:49:54		0.187	1400	OTO 
 
15:49:41		0.187	8600	OTO 
 
15:49:33		0.18	5000	OTO 
 
15:49:11		0.18	1000	OTO 
 
15:47:30		0.18	11000	OTO 
 
15:47:17		0.18	2700	OTO 
 
15:45:53		0.18	2285	OTO 
 
15:45:52		0.18	5000	OTO 
 
15:45:39		0.18	7715	OTO 
 
15:44:59		0.18	5500	OTO 
 
15:43:57		0.18	13650	OTO 
 
15:43:52		0.18	3000	OTO 
 
15:43:13		0.18	950	OTO 
 
15:42:48		0.18	4000	OTO 
 
15:42:48		0.175	7350	OTO 
 
15:39:38		0.175	800	OTO 
 
15:38:13		0.175	50	OTO 
 
15:38:12		0.175	10000	OTO 
 
15:37:38		0.175	7600	OTO 
 
15:37:38		0.175	50	OTO 
 
15:29:38		0.18	10000	OTO 
 
15:24:17		0.18	4835	OTO 
 
15:17:55		0.18	1328	OTO 
 
15:17:47		0.175	8672	OTO 
 
15:15:37		0.175	1328	OTO 
 
15:15:00		0.175	10000	OTO 
 
15:14:53		0.17384	100	OTO 
 
15:14:17		0.175	5000	OTO 
 
15:14:12		0.1694	5000	OTO 
 
15:13:52		0.1694	5000	OTO 
 
15:08:48		0.1694	7000	OTO 
 
15:08:47		0.1694	5000	OTO 
 
15:06:28		0.1694	3000	OTO 
 
15:06:24		0.165	7000	OTO 
 
15:04:49		0.1694	5000	OTO 
 
15:04:38		0.1694	2000	OTO 
 
15:02:48		0.16846	5000	OTO 
 
14:50:10		0.174	600	OTO 
 
14:50:07		0.17	5000	OTO 
 
14:49:42		0.1675	4400	OTO 
 
14:49:25		0.17	2500	OTO 
 
14:47:47		0.165	5000	OTO 
 
14:47:47		0.165	600	OTO 
 
14:47:33		0.165	3000	OTO 
 
14:47:27		0.165	100	OTO 
 
14:42:07		0.16	20	OTO 
 
14:41:22		0.174	5000	OTO 
 
14:41:19		0.174	5000	OTO 
 
14:40:51		0.16	100	OTO 
 
14:40:42		0.16	42400	OTO 
 
14:40:40		0.161	5000	OTO 
 
14:37:34		0.16	5000	OTO 
 
14:37:31		0.16	15000	OTO 
 
14:33:37		0.16	10000	OTO 
 
14:27:44		0.15505	100	OTO 
 
14:27:37		0.15901	100	OTO 
 
14:08:27		0.158	37650	OTO 
 
14:08:25		0.158	20000	OTO 
 
13:31:44		0.158	5000	OTO 
 
13:26:54		0.158	5000	OTO 
 
13:26:51		0.158	5000	OTO 
 
13:18:14		0.15	4552	OTO 
 
13:17:13		0.15	5400	OTO 
 
13:17:11		0.15	9600	OTO 
 
13:16:46		0.15	10000	OTO 
 
13:16:41		0.15	9477	OTO 
 
13:16:13		0.15	710	OTO 
 
13:16:03		0.15	45000	OTO 
 
13:16:03		0.15	7790	OTO 
 
13:15:57		0.15	6500	OTO 
 
13:15:50		0.1505	5000	OTO 
 
13:14:45		0.1515	5000	OTO 
 
13:14:32		0.1515	14000	OTO 
 
12:53:11		0.158	3220	OTO 
 
12:50:10		0.155	5523	OTO 
 
12:41:43		0.156	1000	OTO 
 
12:27:28		0.158	20000	OTO 
 
12:27:15		0.152	5000	OTO 
 
12:23:58		0.1519	5000	OTO 
 
12:22:20		0.152	3944	OTO 
 
12:19:09		0.152	10000	OTO 
 
12:16:50		0.152	7500	OTO 
 
12:16:11		0.152	12556	OTO 
 
12:16:11		0.152	7444	OTO 
 
12:09:32		0.1555	2500	OTO 
 
12:09:28		0.1555	7500	OTO 
 
12:06:39		0.155	6000	OTO 
 
12:06:32		0.16	860	OTO 
 
12:03:47		0.16	1000	OTO 
 
12:03:37		0.155	900	OTO 
 
12:03:24		0.155	100	OTO 
 
11:58:50		0.16	612	OTO 
 
11:58:39		0.16	2500	OTO 
 
11:57:05		0.155	8000	OTO 
 
11:56:21		0.155	7000	OTO 
 
11:50:54		0.157	10000	OTO 
 
11:49:16		0.16	10000	OTO 
 
11:48:46		0.158	5000	OTO 
 
11:48:35		0.158	5000	OTO 
 
11:46:43		0.1572	575	OTO 
 
11:46:10		0.16	400	OTO 
 
11:45:50		0.16	100	OTO 
 
11:43:13		0.16	600	OTO 
 
11:42:58		0.1623	50	OTO 
 
11:42:52		0.16	14600	OTO 
 
11:42:52		0.16	400	OTO 
 
11:42:38		0.16	6000	OTO 
 
11:42:19		0.16	6000	OTO 
 
11:42:18		0.1575	3800	OTO 
 
11:35:07		0.16	3000	OTO 
 
11:25:25		0.155	1200	OTO 
 
11:22:44		0.1505	220	OTO 
 
11:21:41		0.16	10000	OTO 
 
11:21:08		0.1572	1250	OTO 
 
11:19:15		0.16	50	OTO 
 
11:18:54		0.16	100	OTO 
 
11:14:20		0.155	20000	OTO 
 
11:10:48		0.16	2500	OTO 
 
11:10:33		0.155	20000	OTO 
 
11:10:15		0.155	10000	OTO 
 
11:10:09		0.155	25000	OTO 
 
11:07:28		0.1505	975	OTO 
 
11:06:36		0.1505	500	OTO 
 
11:06:22		0.16	20000	OTO 
 
11:05:13		0.16	8000	OTO 
 
11:05:08		0.168	12000	OTO 
 
11:04:28		0.169	5000	OTO 
 
11:04:25		0.169	23000	OTO 
 
11:04:19		0.159	7000	OTO 
 
11:04:18		0.154	10000	OTO 
 
11:03:43		0.156	5000	OTO 
 
11:02:31		0.154	7500	OTO 
 
11:00:28		0.154	10000	OTO 
 
10:58:46                0.154	150	OTO 
 
10:56:04		0.1485	5000	OTO 
 
10:55:23		0.149	10310	OTO 
 
10:55:12		0.149	31000	OTO 
 
10:54:54		0.149	5000	OTO 
 
10:54:52		0.15	5000	OTO 
 
10:54:43		0.149	5000	OTO 
 
10:54:38		0.15	5000	OTO 
 
10:54:25		0.15	19500	OTO 
 
10:53:58		0.149	30000	OTO 
 
10:53:22		0.149	10000	OTO 
 
10:52:46		0.149	21100	OTO 
 
10:52:08		0.144	500	OTO 
 
10:51:06		0.149	2000	OTO 
 
10:48:58		0.149	1900	OTO 
 
10:44:12		0.154	10000	OTO 
 
10:44:05		0.15	20000	OTO 
 
10:43:49		0.149	5000	OTO 
 
10:43:34		0.148	5000	OTO 
 
10:40:26		0.148	4700	OTO 
 
10:35:57		0.148	900	OTO 
 
10:34:41		0.1474	5000	OTO 
 
10:33:36		0.149	10000	OTO 
 
10:31:20		0.1455	3068	OTO 
 
10:31:20		0.154	1932	OTO 
 
10:31:20		0.15	1932	OTO 
 
10:31:17		0.154	5000	OTO 
 
10:31:12		0.154	5000	OTO 
 
10:31:00		0.154	5000	OTO 
 
10:30:11		0.154	1000	OTO 
 
10:23:12		0.147	2817	OTO 
 
10:12:59		0.14	10583	OTO 
 
10:12:49		0.14	1984	OTO 
 
10:12:41		0.138	5000	OTO 
 
10:12:13		0.138	290	OTO 
 
10:10:08		0.138	4710	OTO 
 
10:09:05		0.1364	1450	OTO 
 
10:03:58		0.1362	1450	OTO 
 
09:58:10		0.138	5900	OTO 
 
09:57:57		0.138	100	OTO 
 
09:40:05		0.13	20000	OTO 
 
09:39:43		0.13	4000	OTO  
 
09:38:49		0.13	10000	OTO  
 
09:35:08		0.13	8590	OTO 
 
09:33:55		0.13	3100	OTO 
 
09:33:27		0.128	10356	OTO  
 
09:33:17		0.128	3044	OTO .. @ bid (mine) set pre mkt  
 
09:30:49		0.13	14800	OTO 
 
09:30:40		0.1304	100	OTO 
 
09:30:06		0.128	47	OTO .. 47 + 53 + 100  
 
09:30:01		0.12955	53	OTO .. 53 + 47 + 100

since K was filed on 9.11.18 ..

November 1, 2018
INNOVATION PHARMACEUTICALS EXPANDS BRILACIDIN PATENT PORTFOLIO

October 24, 2018
INNOVATION PHARMACEUTICALS GRANTED END-OF-PHASE 2 MEETING

October 22, 2018
INNOVATION PHARMACEUTICALS PROVIDES UPDATE ON KEVETRIN PROGRAM; BRIDGING TOXICOLOGY EFFORTS AIMED AT DEVELOPING AN ORAL P53 ANTI-CANCER DRUG CANDIDATE

October 12, 2018
INNOVATION PHARMACEUTICALS BRILACIDIN AS A NOVEL INHIBITOR OF PHOSPHODIESTERASE 4 (PDE4) SUPPORTS ITS POTENTIAL TO TREAT AUTOIMMUNE AND INFLAMMATORY DISEASES

October 9, 2018
INNOVATION PHARMACEUTICALS SECURES UP TO $10 MILLION IN ADDITIONAL FINANCING TO ADVANCE CLINICAL PIPELINE

September 24, 2018
INNOVATION PHARMACEUTICALS PROVIDES A COMPARATIVE PERSPECTIVE ON BRILACIDIN’S POTENTIAL TO UNLOCK THE ORAL MUCOSITIS MARKET: PHARMA INDUSTRY ATTACKS SEVERE PAIN AND SUFFERING DUE TO CANCER TREATMENTS

September 20, 2018
INNOVATION PHARMACEUTICALS PROVIDES CORPORATE UPDATE HIGHLIGHTING UPCOMING MILESTONES AND EVENTS

http://www.ipharminc.com/press-release/

 
 
Form Type	Description	Filing Date	 
 
8-K	Current report, item 7.01	2018-10-24	  
 
4	Statement of changes in beneficial ownership ...	2018-10-16	 
 
4	Statement of changes in beneficial ownership ...	2018-10-15	 
 
8-K	Current report, item 7.01	2018-10-10	 
 
8-K	Current report, items 1.01, 5.03, 7.01, and 9...	2018-10-09	  
 
424B5	Prospectus	2018-10-09	 
 
4	Statement of changes in beneficial ownership ...	2018-09-24	 
 
4	Statement of changes in beneficial ownership ...	2018-09-24	 
 
8-K	Current report, item 5.02	2018-09-21	 
 
10-K	Annual report	2018-09-11

http://www.ipharminc.com/financials/

a good weekend to all Innovation Pharma Investors ..

4kids

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AEVEX Faces Legal Scrutiny Amid Secondary Offering Stir

AEVEX on the Legal Hook: What's Going Down? Look, nobody likes bad news, especially when their pockets feel the pinch. AEVEX Corp. (NYSE: AVEX) kicked up quite the dust cloud when their stock plummeted after a secondary offering—dropping a whopping 16% at first glance, and then an extra seven in the blink of an eye. Timing Is Everything in the Stock Game Set the stage:...

Laredo Oil Eyes Big Gains in Argentina's Oil Play

Argentina's Oil Play: Laredo Oil's Bold Venture Talk about shooting for the stars. Laredo Oil's second tête-à-tête with Santa Cruz Province's big wigs highlights their itch to rejuvenate Argentina's tired oil fields. For folks who know the nitty-gritty of oil, we're talking about the Golfo San Jorge Basin, a place where old dogs might learn new tricks thanks to that...

CourseArc Partners with Colleges for ADA Compliance

CourseArc's Landmark Deal with Public Colleges Well, slap me silly and call me a believer—looks like CourseArc just locked down a heck of a gig with a public college system that's head-over-heels squirming to meet shiny new accessibility demands. Nearly 200,000 learners are waiting at their gates, and this agreement is the lifeline for colleges to not only stay afloat...

Glint: Lovense's New Era in Intimacy Tech

From Thrill to Touch: The Glint Debut Screw the traditional remote control for sex toys! Lovense is straight up flipping the script with Glint. This isn't about adding more buttons or connecting another app. We're talking about a butt plug that lets your partner's thrust set the whole vibe. Forget fumbling with phones in the heat of the moment—this toy syncs your...

Top Gun F/A-18 Super Hornet Lands at Palm Springs

Aviation Marvel Now Anchored at Palm Springs There's something electric about standing next to a piece of history, especially when it involves the thunderous scream of an F/A-18 Super Hornet. The Palm Springs Air Museum is pulling back the curtains on an experience that's got aviation buffs and Top Gun fans buzzing like bees. On November 7, 2026, this central hub of...

Baidu Faces Class Action Over Misleading AI Revenue Claims

Another Day, Another Lawsuit Nothing says 'start your week' quite like the sounds of courtroom battles echoing across the market landscape. Baidu, Inc. (NASDAQ: BIDU) finds itself in the legal crosshairs, courtesy of the DJS Law Group. They're being accused of some shady dealings, and the core of this drama is all about what they claimed versus the reality of their...

Freight Rebound Sparks Strategic M&A Opportunities

Is the Freight Recovery Here to Stay? Just when you thought trucking might have run out of gas, we're hitting a sharp turn back into growth town. For those of you dropping equity crumbs every which way but loose in the last few years, this freight lull has been brutal—like the hangover from hell. But Brown Gibbons Lang & Company’s fresh report now hints at a brighter...

AI Agents Race: 10M Downloads Spark Competitive Fire

The AI Agent Arms Race is On Throwdown time in the AI jungle, folks. A new AI agent hit the big 10.9 million downloads in a mere six weeks. In the digital world, those kinds of numbers are the equivalent of finding a unicorn in your backyard. This data gem comes courtesy of Sensor Tower, as reported by Yahoo Finance, and it looks like the appetite for this technological...

IOS Financing Evolution: A Closer Look at New Trends

Unlocking New Avenues in IOS Financing I tell you, it's a jungle out there in the industrial outdoor storage (IOS) sector, and someone just handed us a map. The sector's booming, and Partner Valuation Advisors dropped a bombshell report by Vytas Norusis that's already turning heads. We're talking about financing structures evolving faster than your morning coffee can get...

Alaska Air Group's Q3: Facing Headwinds and Strategies

Weathering the Q3 Storm Alaska Air Group's third quarter results are in the bag, and let me tell ya, it's a mixed bag of sour lemons and hopeful limes. Reporting a net loss of $147 million or ($1.32) per share ain't the kind of results that plaster smiles on investors' faces. But hey, it's a volatile sector if there ever was one, especially with fuel costs ballooning to a...